Elizabeth COHEN-JONATHAN MOYAL
Institut Claudius Regaud
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elizabeth COHEN-JONATHAN MOYAL as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:39 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01118676 · Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung CancerInstitut Claudius Regaud · completed · Locally Advanced Non Small Cell Lung Cancer (NSCLC) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:39 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.Int J Radiat Oncol Biol Phys · 200874 citationsRCR 2.2
- Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.Int J Radiat Oncol Biol Phys · 200735 citationsRCR 0.8
- Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.Eur Radiol · 201622 citationsRCR 0.9
- Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.J Neurooncol · 20158 citationsRCR 0.3